Orphan designation: Fosmanogepix Treatment of mucormycosis, 15/02/2023 Positive
Submitted by Anonymous (not verified) on 2 October 2024 - 15:40
Orphan designation: Fosmanogepix Treatment of mucormycosis, 15/02/2023 Positive
EMEA-003220-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 15:21
EMEA-003220-PIP01-22
CHMP PROM minutes for the meeting on 15 July 2024
Submitted by Anonymous (not verified) on 2 October 2024 - 15:10
CHMP PROM minutes for the meeting on 15 July 2024
Improving efficiency of approval process for new medicines in the EU
Submitted by Anonymous (not verified) on 2 October 2024 - 14:00
Improving efficiency of approval process for new medicines in the EU
EMEA-003059-PIP02-23
Submitted by Anonymous (not verified) on 2 October 2024 - 13:55
EMEA-003059-PIP02-23
EMEA-003154-PIP01-21
Submitted by Anonymous (not verified) on 2 October 2024 - 13:55
EMEA-003154-PIP01-21
EMEA-002850-PIP03-22
Submitted by Anonymous (not verified) on 2 October 2024 - 13:45
EMEA-002850-PIP03-22
EMEA-002438-PIP04-23
Submitted by Anonymous (not verified) on 2 October 2024 - 13:15
EMEA-002438-PIP04-23
EMEA-002451-PIP03-22
Submitted by Anonymous (not verified) on 2 October 2024 - 13:15
EMEA-002451-PIP03-22
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neurology, PIP number: P/0298/2023
Submitted by Anonymous (not verified) on 2 October 2024 - 13:00
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neurology, PIP number: P/0298/2023